In this editoral, the writers warn that pharmaceutical company marketing to physicians has become more sublte, and physicians should be aware of how marketing tactics influence industry sponsorship on clinical practice guidelines, consensus conferences, narrative and systematic reviews and continuing professional development. Furthermore, the authors argue that conflicts of interest should be disclosed when they are witnessed.